• Home>
  • Stocks>
  • Glenmark Pharmaceuticals Ltd Share Price
Glenmark Pharmaceuticals Ltd share price logo

Glenmark Pharmaceuticals Ltd Share Price

(GLENMARK)

₹1349.45▲1.46%

as on 02:59PM, 20 Feb 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Option Chain

Glenmark Pharmaceuticals Ltd Performance

  • Day's Low

    Day's High

    ₹1,343.2
    Day's Price Range
    ₹1,385.7

  • 52 Week's Low

    52 Week's High

    ₹853
    52-Week Price Range
    ₹1,830.95
1 Month Return-8.92 %
3 Month Return-6.61 %
1 Year Return+ 53.16 %
Previous Close₹1,369.45
Open₹1,349.70
Volume5.94L
Upper Circuit-
Lower Circuit-
Market Cap₹38,644.26Cr

Glenmark Pharmaceuticals Ltd Key Statistics

P/E Ratio

-219.82

PEG Ratio

-11.58

Market Cap

₹38,644.26 Cr

P/B Ratio

1.18

EPS

-50.8

Dividend Yield

0.26

Sector

Pharmaceuticals

ROE

6.98

Glenmark Pharmaceuticals Ltd Analyst Rating

based on 13 analysts

BUY

61.54%

Buy

30.77%

Hold

7.69%

Sell

Based on 13 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹1741.46

Source: S&P Global Market Intelligence

Glenmark Pharmaceuticals Ltd Share analysis

Glenmark Pharmaceuticals Ltd price forecast by 13 analysts

Upside of27.16%

High

₹2036

Target

₹1741.46

Low

₹1345

Glenmark Pharmaceuticals Ltd target price ₹1741.46, a slight upside of 27.16% compared to current price of ₹1349.45. According to 13 analysts rating.

Source: S&P Global Market Intelligence

Key events for Glenmark Pharmaceuticals Ltd

  • Glenmark Faces Recall Amid Positive Growth Outlook - 18 Feb, 2025

    Glenmark Pharmaceuticals is recalling Carvedilol tablets in the US due to impurity issues. Despite this, analysts maintain a positive outlook with strong growth projections and product launches.

  • Glenmark Reports Strong Q3 Profit and Growth - 17 Feb, 2025

    Glenmark Pharmaceuticals returned to profitability in Q3 FY25 with a net profit of Rs 348 crore, driven by a 300% revenue increase in India. The company maintains a positive outlook despite challenges in the acute respiratory business and plans for new product launches.

  • Glenmark Reports Strong Q3 and New Product Launch - 14 Feb, 2025

    Glenmark Pharmaceuticals launched a generic Latanoprost solution and reported a consolidated profit of ₹348 crore for Q3 FY25, highlighting robust regional growth despite a USFDA inspection.

  • Glenmark Launches New Acne Treatment in US Market - 12 Feb, 2025

    Glenmark Pharmaceuticals has launched Clindamycin Phosphate Foam, a generic version of Evoclin Foam, in the US. This product aims to provide a cost-effective acne treatment option, reinforcing Glenmark's commitment to dermatology.

  • Glenmark Secures Winlevi Approval Amid Tax Order - 10 Feb, 2025

    Glenmark Pharmaceuticals received MHRA approval for Winlevi, a new acne treatment, while also facing a tax order of INR 121.25 crore. The stock rose 0.6% following positive financial results, showing a revenue increase and profit turnaround in Q2 FY25.

  • Glenmark Faces GST Demand, Buy Recommendation Issued - 08 Feb, 2025

    Glenmark Pharmaceuticals received a ₹121.25 crore GST demand but plans to appeal, asserting no material impact. A market expert recommends buying shares with a target price of Rs 1570.

  • Glenmark Launches New Injectable Emulsion, Shares Rise - 21 Jan, 2025

    Glenmark Pharmaceuticals launched Phytonadione Injectable Emulsion in the US, addressing blood clotting issues. The announcement led to a 2% increase in share price.

  • Glenmark's Drug Shows Promise Against Cancer - 20 Jan, 2025

    Glenmark Pharmaceuticals' Ichnos drug demonstrates promising results in treating multiple myeloma, a rare blood cancer, potentially challenging major pharmaceutical companies in a growing market projected to reach USD 30 billion by the decade's end.

Insights on Glenmark Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, GLENMARK stock has moved up by 53.2%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 23.05% to 23.51% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 11.41% to 12.12% in Dec 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 59.9% return, outperforming this stock by 6.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 46.65% of holdings in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 17.06% to 15.96% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 354.21 Cr → 347.96 Cr (in ₹), with an average decrease of 1.8% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 3.47K Cr → 3.41K Cr (in ₹), with an average decrease of 1.6% per quarter

Glenmark Pharmaceuticals Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹2,460.29Cr (-)₹3,016.01Cr (↑22.59%)₹3,223.30Cr (↑6.87%)₹3,400.50Cr (↑5.50%)₹3,301.90Cr (↓2.90%)
Net Income-₹330.82Cr (-)-₹1,214.27Cr (↑267.05%)₹340.24Cr (↓128.02%)₹354.49Cr (↑4.19%)₹348.03Cr (↓1.82%)
Net Profit Margin-13.45% (-)-40.26% (↑199.33%)10.56% (↓126.23%)10.42% (↓1.33%)10.54% (↑1.15%)
Value in ₹ crore
Details2021202220232024
Total Assets₹20,882.95Cr (-)₹23,128.70Cr (↑10.75%)₹24,799.42Cr (↑7.22%)₹27,724.16Cr (↑11.79%)
Total Liabilities₹6,073.44Cr (-)₹6,390.11Cr (↑5.21%)₹6,921.95Cr (↑8.32%)₹4,753.54Cr (↓31.33%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹1,579.12Cr (-)₹1,243.42Cr (↓21.26%)₹1,216.07Cr (↓2.20%)₹1,474.06Cr (↑21.22%)-₹495.45Cr (↓133.61%)

Index Inclusions

Nifty Healthcare

₹13,379.55

0.12 (▲15.7%)

BSE Healthcare

₹40,275.44

0.43 (▲171.3%)

BSE Mid-Cap

₹40,842.54

1.15 (▲465.86%)

S&P BSE 250 LargeMidCap

₹9,776.69

0.36 (▲35.4%)

NIFTY PHARMA

₹20,774.25

-0.22 (▲-45.75%)

Nifty MidSmallcap 400

₹17,393.80

1.24 (▲212.85%)

Nifty Smallcap 50

₹7,631.45

1.63 (▲122.4%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

Nifty Alpha 50

₹45,849.70

1.77 (▲795.3%)

Nifty 500

₹20,821.45

0.43 (▲90%)

S&P BSE 150 MidCap

₹14,170.63

1.2 (▲168.4%)

Nifty Small 100

₹15,744.40

1.41 (▲218.5%)

Nifty Smallcap 250

₹14,775.00

1.28 (▲186.35%)

S&P BSE 400 MidSmallCap

₹10,580.38

1.21 (▲126.33%)

BSE 500

₹32,755.47

0.45 (▲147.7%)

Glenmark Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
46.65%
0.00
Foreign Institutions
23.51%
1.99
Mutual Funds
12.12%
6.20
Retail Investors
15.96%
-6.43
Others
1.77%
-3.72

Glenmark Pharmaceuticals Ltd Key Indicators

Details20202021202220232024
Return On Equity %10.7611.7710.429.126.98
Details20202021202220232024
Return On Assets %4.044.654.071.2-5.42
Details20202021202220232024
Book Value Per Share (₹)215.14250.37322.03335.75278.11
Details20202021202220232024
Earning Per Share (₹)27.534.3835.2113.37-50.8

Glenmark Pharmaceuticals Ltd Valuation

Glenmark Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (-275.05x)

December 28, 2023

Today (-219.82x)

February 19, 2025

Industry (51.87x)

February 19, 2025

Highest (95.94x)

September 14, 2023

LowHigh

Glenmark Pharmaceuticals Ltd Earnings and Dividends

  • Glenmark Pharmaceuticals Ltd Earnings Results

    Glenmark Pharmaceuticals Ltd’s net profit jumped 199.03% since last year same period to ₹347.96Cr in the Q3 2024-2025. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated -1.76% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Glenmark Pharmaceuticals Ltd Dividends May,2024

    In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.18%.

    Read More about Dividends

Glenmark Pharmaceuticals Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Glenmark Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

Glenmark Pharmaceuticals Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
BUY₹38,644.26 Cr65.18%0.52-₹1,434 Cr₹11,813 Cr
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
BUY₹29,528.26 Cr117.66%0.52₹300 Cr₹1,051 Cr
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
BUY₹15,427.41 Cr20.84%0.57₹72 Cr₹6,702 Cr
Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd
NA₹4,270.70 Cr-4.25%0.79-₹388 Cr₹75 Cr
Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Ltd
BUY₹13,039.23 Cr37.04%0.68₹218 Cr₹1,296 Cr
See all

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is an Indian pharmaceuticals company listed on the National Stock Exchange and Bombay Stock Exchange. Established in 1977, the company manufactures and distributes branded and generic formulations, active pharmaceutical ingredients (API’s) and biosimilars. It has 18 manufacturing facilities in India, 7 in the U.S., 1 in Brazil and 1 in Mexico that span across the world catering to global requirements. Glenmark has taken several steps towards achieving a healthy presence in the global markets. In addition to its product portfolio, Glenmark’s aggressive acquisition strategy and product launch activities have helped expand its market reach. The company has been awarded numerous accolades over the years, including consecutive years of being ranked amongst the top 1000 world pharmaceutical companies. It continues to be a frontrunner in providing quality and affordable healthcare solutions in India and abroad.

Share Price: ₹1349.45 per share as on 20 Feb, 2025 02:59 PM
Market Capitalisation: ₹38,644.26Cr as of today
Revenue: ₹3,301.90Cr as on December 2024 (Q4 24)
Net Profit: ₹348.03Cr as on December 2024 (Q4 24)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Pharmaceuticals Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Glenmark Pharmaceuticals Ltd

What is Glenmark Pharmaceuticals Ltd price today?

Glenmark Pharmaceuticals Ltd share price today stands at ₹1349.45, Open: ₹1349.7, Previous Close: ₹1369.45, High: ₹1385.7, Low: ₹1343.2, 52 Week High: ₹1830.95, 52 Week Low: ₹853.

How to Buy Glenmark Pharmaceuticals Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Glenmark Pharmaceuticals Ltd shares

Is Glenmark Pharmaceuticals Ltd listed on NSE?

Glenmark Pharmaceuticals Ltd is listed on NSE

Is Glenmark Pharmaceuticals Ltd listed on BSE?

Glenmark Pharmaceuticals Ltd is listed on BSE

What are today's High and Low prices of Glenmark Pharmaceuticals Ltd?

  • Today's highest price of Glenmark Pharmaceuticals Ltd is ₹1385.7.
  • Today's lowest price of Glenmark Pharmaceuticals Ltd is ₹1343.2.

What are today's traded volumes of Glenmark Pharmaceuticals Ltd?

Today's traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 5.94L.

What is today's market capitalisation of Glenmark Pharmaceuticals Ltd?

Today's market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹38644.26Cr.

What is the 52 Week High and Low Range of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd (GLENMARK)
Price
52 Week High
₹1830.95
52 Week Low
₹853

How much percentage Glenmark Pharmaceuticals Ltd is down from its 52 Week High?

Glenmark Pharmaceuticals Ltd (GLENMARK) share price is ₹1349.45. It is down -26.30% from its 52 Week High price of ₹1830.95

How much percentage Glenmark Pharmaceuticals Ltd is up from its 52 Week low?

Glenmark Pharmaceuticals Ltd (GLENMARK) share price is ₹1349.45. It is up 58.20% from its 52 Week Low price of ₹853

What are the historical returns of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd (GLENMARK)
Returns
1 Day Returns
-20%
1 Month Returns
-8.92%
3 Month Returns
-6.61%
1 Year Returns
53.16%

What is the PE ratio of Glenmark Pharmaceuticals Ltd today?

PE Ratio of Glenmark Pharmaceuticals Ltd is -219.82

PE ratio = Glenmark Pharmaceuticals Ltd Market price per share / Glenmark Pharmaceuticals Ltd Earnings per share